Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation.
about
Direct estradiol and diethylstilbestrol actions on early- versus late-stage prostate cancer cells.Mixed ligand μ-phenoxo-bridged dinuclear copper(II) complexes with diimine co-ligands: efficient chemical nuclease and protease activities and cytotoxicity.Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesisPathophysiology of tumor neovascularization.Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues.miR-146a promotes the initiation and progression of melanoma by activating Notch signaling.Current State of Metal-Based Drugs for the Efficient Therapy of Lung Cancers and Lung Metastases.Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging PropertiesSolvent assisted formation of ruthenium(III) and ruthenium(II) hydrazone complexes in one-pot with potential in vitro cytotoxicity and enhanced LDH, NO and ROS release.RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A.Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2.Bone marrow mesenchymal stromal cells affect the cell cycle arrest effect of genotoxic agents on acute lymphocytic leukemia cells via p21 down-regulation.The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure.
P2860
Q34381523-F232A706-D7C6-47B6-9DA2-684CD28E1727Q35111438-BD0FD967-039B-4261-BA67-FEFBF465A2D0Q36007575-9876C013-830D-4C3D-8FED-1E53B5024CA3Q36742274-B1CEF01B-FDA8-485C-A51C-63D05CF2BFCFQ37340375-1B8F03EA-BB67-4848-B537-06B4286371FAQ37424157-2A8BDAA9-1399-4939-B915-3B5818E0FBF6Q37590529-15267C76-8032-41F9-9A87-D1BD6D4A506CQ38669290-B3F218B7-CC9D-4A76-9870-351CA7D4D9A4Q38753875-D40E2195-EBD5-4491-B0EE-D631C00B72C0Q38809475-F69AB0CF-F315-4856-8876-6F962C752100Q38838114-4E036F54-7C9D-4EC1-A6E4-C39F700A3754Q39220891-FD2E798E-EC04-445B-9D27-4D4F9680ED73Q40737623-7C32B34C-9B81-4870-821A-56B7422F5D7CQ42330186-1C706FFA-B5CC-4ED5-8689-9A11AABDC5FBQ53059153-8C263540-34C8-409A-B6C9-4F355C878D5DQ53503817-D8BB0469-B46B-4BAA-9711-7FD6A6C307D6
P2860
Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Inhibition of the MEK/ERK sign ...... ndothelial cell proliferation.
@en
type
label
Inhibition of the MEK/ERK sign ...... ndothelial cell proliferation.
@en
prefLabel
Inhibition of the MEK/ERK sign ...... ndothelial cell proliferation.
@en
P2093
P2860
P1433
P1476
Inhibition of the MEK/ERK sign ...... ndothelial cell proliferation.
@en
P2093
Anna Maria Posadino
Bastiano Sanna
Bruna Tadolini
Carlo Ventura
Federico Bennardini
Gianfranco Pintus
Marcella Debidda
P2860
P304
P356
10.1046/J.1432-1033.2002.03307.X
P407
P50
P577
2002-12-01T00:00:00Z